China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies
Simnova Biotech has secured nearly CNY400 million (USD59.5 million) in its latest funding round to accelerate clinical research of the Chinese cell therapy startup’s off-the-shelf cell therapies, the firm said today. The Series B funding round was co-led by Shanghai state-owned investment funds Fortera Capital and Pudong Venture Capital, along with private equity firm Cenova Ventures, Shanghai-based Simnova said. Suzhou state-owned investment firm Oriza Holdings participated as a follow-on investor, while existing shareholder Youshan Capital increased its investment.
Share:
More News
AstraZeneca announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
“This agreement represents an important step in our strategy to advance our most promising ADC programs efficiently while preserving long-term value,” said Ashutosh Tiwari, PhD, Chief Executive Officer of Styx Biotechnologies. “This collaboration creates a capital-efficient path to first-in-human development by allowing Styx to clinically de-risk selected programs while preserving
“What is most exciting to us is the depth and durability of the responses we are seeing with INBRX-106, particularly in HPV+ disease,” said Mark Lappe, co-founder and Chief Executive Officer of Inhibrx. “These results strengthen our conviction in OX40-mediated T-cell costimulation and give us a strong rationale to expand
“CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche,” said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. “We have generated exciting preclinical data suggesting that TLN-121 enhances